Eikonoklastes Announces Formation of Scientific Advisory Board – Gene Therapy
15 May 2023 //
BUSINESSWIRE
Eikonoklastes and Forge Biologics Announce Viral Vector Contract Development
29 Nov 2022 //
BUSINESSWIRE
Eikonoklastes Receives FDA Orphan Drug Designation for 1st-in-class (ALS)
09 Nov 2022 //
BUSINESSWIRE
Eikonoklastes Bolsters Pipeline, Announces a License for Novel Gene Therapy
19 Jan 2022 //
BUSINESSWIRE